Intuitive Surgical, Inc. $ISRG Shares Purchased by Envestnet Portfolio Solutions Inc.

Key Points

• Envestnet Portfolio Solutions Inc. increased its stake in Intuitive Surgical, Inc. by 25.8%, owning 40,755 shares valued at $22.15 million as of the last quarter.
• Intuitive Surgical reported a strong earnings result, with a net margin of 28.51% and revenue of $2.44 billion, exceeding analysts' expectations.
• Major insider sales included Gary S. Guthart, who sold 29,360 shares, representing a 59.69% decrease in his ownership, amidst an overall pattern of insider selling in recent months.

Envestnet Portfolio Solutions Inc. boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 25.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 40,755 shares of the medical equipment provider's stock after buying an additional 8,355 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Intuitive Surgical were worth $22,147,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Chilton Capital Management LLC grew its holdings in shares of Intuitive Surgical by 614.3% in the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 43 shares during the period. Elite Financial Inc. acquired a new position in Intuitive Surgical in the 1st quarter valued at about $26,000. LFA Lugano Financial Advisors SA purchased a new stake in shares of Intuitive Surgical in the 1st quarter valued at approximately $30,000. TD Capital Management LLC lifted its holdings in Intuitive Surgical by 300.0% in the first quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock valued at $30,000 after acquiring an additional 45 shares during the last quarter. Finally, 1248 Management LLC acquired a new stake in Intuitive Surgical during the first quarter worth $30,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Price Performance

Shares of ISRG opened at $429.59 on Monday. The stock has a market cap of $154.00 billion, a PE ratio of 59.91, a price-to-earnings-growth ratio of 4.51 and a beta of 1.61. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $616.00. The firm has a fifty day moving average price of $458.68 and a 200 day moving average price of $497.84.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. During the same period in the prior year, the company earned $1.78 earnings per share. The business's revenue was up 21.4% compared to the same quarter last year. As a group, equities analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Insider Activity at Intuitive Surgical

In other news, insider Gary S. Guthart sold 29,360 shares of the business's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the transaction, the insider directly owned 19,827 shares in the company, valued at $9,368,059.23. The trade was a 59.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Amy L. Ladd sold 336 shares of the stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $470.11, for a total transaction of $157,956.96. Following the transaction, the director directly owned 1,074 shares of the company's stock, valued at $504,898.14. This represents a 23.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 45,224 shares of company stock worth $21,716,492 in the last three months. Insiders own 0.70% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ISRG. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Intuitive Surgical in a research note on Wednesday, October 8th. Truist Financial upped their target price on shares of Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Zacks Research cut shares of Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Intuitive Surgical in a report on Friday, August 22nd. Finally, BTIG Research reiterated a "buy" rating and issued a $571.00 target price on shares of Intuitive Surgical in a report on Wednesday, October 1st. Fourteen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $589.43.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.